Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Lymphoma, Follicular × sargramostim × Clear all

Phase

Status

Sponsor Class

OTHER 17 NIH 8 NETWORK 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myeloid, Acute 5 Glioblastoma 3 Pathologic Complete Response 2 Ovarian Neoplasms 2 Neoplasms 2 Multiple Myeloma 2 Melanoma 2 Lung Neoplasms 2 Gliosarcoma 2 Colorectal Neoplasms 2 Carcinoma, Renal Cell 2 Carcinoma, Non-Small-Cell Lung 2 Breast Neoplasms 2 Wilms Tumor 1 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumor 1 Smoldering Multiple Myeloma 1 Small Cell Lung Carcinoma 1 Prostatic Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Neoplasm Metastasis 1 Myelodysplastic Syndromes 1 Lymphoma, Follicular 1 Glioma 1 Brain Neoplasms 1 Advanced Ovarian Cancer 1 Advanced Cancer 1

Interventions

Rituximab 78 Cyclophosphamide 27 Lenalidomide 24 Bendamustine Hydrochloride 22 Prednisone 18 Vincristine 17 Doxorubicin 15 obinutuzumab 13 fludarabine 11 ibrutinib 9 tazemetostat 8 parsaclisib 8 idelalisib 8 Deoxycholic Acid 8 zanubrutinib 7 Prednisolone 7 venetoclax 6 tofacitinib 6 tisagenlecleucel 5 pembrolizumab 5 duvelisib 5 Gemcitabine 5 ibritumomab tiuxetan 4 aflibercept 4 R-CHOP protocol 4 Methylprednisolone 4 Methotrexate 4 Bortezomib 4 ublituximab 3 pixantrone 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00308087 2013-12-27

PREMIER

Sanofi

Phase 2 Terminated

75 enrolled 12 charts

Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡